ArticleBMC microbiology2020
Size-dependent activity of silver nanoparticles on the morphological switch and biofilm formation of opportunistic pathogenic yeasts.
Article in BMC microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Fungal-mediated green synthesis of ZnO-MnO nanocomposites with antimicrobial and anticancer properties.Scientific reports · 2026Article
- A comparative evaluation of green colloidal silver variants for enhanced stability and bioactivity.Scientific reports · 2025Article
- Unveiling the antifungal and antibiofilm potential of green synthesized silver nanoparticles from leaf extract of Selaginella bryopteris.Scientific reports · 2025Article
- Fungal Biofilm: An Overview of the Latest Nano-Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial and Antifungal Action of Biogenic Silver Nanoparticles in Combination with Antibiotics and Fungicides Against Opportunistic Bacteria and Yeast.International journal of molecular sciences · 2024Article
- Development and characterization of three-dimensional antibacterial nanocomposite sponges of chitosan, silver nanoparticles and halloysite nanotubes.RSC advances · 2024Article
- Unravelling the Antimicrobial, Antibiofilm, SuppressingMedicina (Kaunas, Lithuania) · 2024Article
- Article
- Bimetallic AgPt Nanoalloys as an Electrocatalyst for Ethanol Oxidation Reaction: Synthesis, Structural Analysis, and Electro-Catalytic Activity.Nanomaterials (Basel, Switzerland) · 2023Article
- Article
- Natural Strategies as Potential Weapons against Bacterial Biofilms.Life (Basel, Switzerland) · 2022Review
- Trehalose-Modified Silver Nanoparticles as Antibacterial Agents with Reduced Cytotoxicity and Enhanced Uptake by Mycobacteria.ACS applied nano materials · 2022Article
- A Promising Antifungal and Antiamoebic Effect of Silver Nanorings, a Novel Type of AgNP.Antibiotics (Basel, Switzerland) · 2022Article
- Physiological Response ofJournal of fungi (Basel, Switzerland) · 2022Article
- Nanodelivery of antiretroviral drugs to nervous tissues.Frontiers in pharmacology · 2022Review
- Recent advances in nanotechnology for eradicating bacterial biofilm.Theranostics · 2022Review
- Effect of Cannabis Smoke Condensate onMicroorganisms · 2021Article
- Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?Nanomaterials (Basel, Switzerland) · 2021Review
- In Vitro Antifungal Activity of Silver Nanoparticles Biosynthesized with Beech Bark Extract.Plants (Basel, Switzerland) · 2021Article
- Polyvinyl-Pyrrolidone-Coated Silver Nanoparticles-The Colloidal, Chemical, and Biological Consequences of Steric Stabilization under Biorelevant Conditions.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDimorphism and biofilm formation are important virulence factors of some opportunistic human pathogenic yeasts. Such species commensally colonize skin or mucosal surfaces generally in yeast form, but under particular circumstances, convert into virulent hyphae and disseminate internal organs or cause mucocutaneous infections. The yeast-to-hypha shape-conversion promotes the development of a biofilm, a thick extracellular matrix with sessile cells within. The biofilm is capable to prevent the penetration of antifungal drugs, rendering the surviving biofilm-resident cells intrinsic sources of recurrent infections. The aim of this study was to evaluate the ability of silver nanoparticles (AgNPs) to attenuate the morphological switch and biofilm formation of several opportunistic pathogenic yeasts and to determine whether this feature depends on the nanoparticle size.
resultsAgNPs in three different sizes were prepared by chemical reduction approach and characterized by transmission electron microscopy, ultraviolet-visible spectroscopy and dynamic light scattering. The antifungal activity was evaluated by the microdilution method, the inhibitory capacity on biofilm formation and the biofilm degradation ability of differently sized AgNPs was assessed by viability assay. The morphological state of opportunistic pathogenic yeast cells in monoculture and in co-culture with human keratinocytes in the presence of AgNPs was examined by flow cytometry and scanning electron microscopy. All the three AgNPs inhibited the growth of the examined opportunistic pathogenic yeasts, nevertheless, AgNPs with the smallest diameter exhibited the most prominent toxic activities. AgNPs attenuated the biofilm formation in a nanoparticle size-dependent manner; however, their biofilm destruction capacity was negligible. AgNPs with the smallest size exerted the most significant effect on suppressing the morphological change of pathogens in monoculture as well as in a co-culture with keratinocytes.
conclusionsOur results confirm that AgNPs are capable to hinder yeast-to-hypha morphological conversion and biofilm formation of opportunistic pathogens and this biological effect of AgNPs is size-dependent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.